Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 17.72 | 12.78 | 28.62 | 24.55 | 10.32 | 10.25 | 21.81 | 22.09 | 22.77 | 21.17 | 38.38 | 21.55 | 23.14 | 21.13 | 28.65 | 17.18 | 14.77 | 19.78 | 20.28 | 8.02 | 10.56 |
| — | +24.7% | +31.2% | +11.1% | -54.7% | -51.6% | -43.2% | +2.5% | -1.6% | +0.2% | +34.0% | +25.4% | +56.7% | +6.8% | +41.3% | +114.2% | +39.9% | +296.3% | +73.0% | -32.0% | -44.2% | |
| P/S Ratio | 5.28 | 3.88 | 5.77 | 5.34 | 4.01 | 3.88 | 5.82 | 5.35 | 8.21 | 8.55 | 8.81 | 7.28 | 6.94 | 6.48 | 7.41 | 6.02 | 6.62 | 5.90 | 6.66 | 3.61 | 4.99 |
| — | +0.1% | -0.9% | -0.1% | -51.1% | -54.6% | -33.9% | -26.5% | +18.3% | +31.9% | +18.9% | +20.8% | +4.9% | +9.9% | +11.2% | +66.9% | +32.6% | +95.8% | +28.8% | -35.5% | -28.2% | |
| P/B Ratio | 2.55 | 2099461.28 | 2.65 | 2.65 | 1.95 | 1.90 | 2.40 | 2.76 | 4.17 | 4.30 | 4.10 | 3.85 | 3.75 | 3.41 | 3.99 | 3.63 | 3.62 | 3.26 | 3.97 | 3.81 | 3.99 |
| — | +110243803.1% | +10.3% | -3.9% | -53.3% | -55.7% | -41.5% | -28.2% | +11.2% | +26.2% | +3.0% | +6.0% | +3.4% | +4.6% | +0.5% | -4.7% | -9.3% | -20.4% | -9.2% | -22.5% | -36.6% | |
| P/FCF | 18.56 | 49.80 | 24.52 | 22.50 | 10.63 | 14.73 | 22.79 | 20.35 | 27.57 | 211.90 | 20.50 | 32.19 | 24.87 | 22.50 | 19.69 | 13.12 | 39.94 | 41.01 | 10.08 | 8.06 | 5.25 |
| — | +238.1% | +7.6% | +10.6% | -61.4% | -93.0% | +11.2% | -36.8% | +10.9% | +841.8% | +4.1% | +145.4% | -37.7% | -45.1% | +95.4% | +62.8% | +660.3% | +26.8% | -57.4% | -36.4% | — | |
| EV / EBITDA | 18.28 | 17.18 | 27.07 | 20.14 | 12.99 | 11.88 | 24.40 | 18.20 | 23.60 | 25.64 | 32.03 | 21.47 | 17.83 | 18.45 | 20.97 | 14.46 | 14.61 | 12.07 | 14.39 | 6.57 | 8.88 |
| — | +44.6% | +10.9% | +10.7% | -44.9% | -53.7% | -23.8% | -15.2% | +32.4% | +39.0% | +52.7% | +48.5% | +22.0% | +52.8% | +45.7% | +120.1% | +64.5% | +164.0% | +26.9% | -41.0% | -39.1% | |
| EV / EBIT | 21.05 | 15.24 | 24.57 | 19.55 | 8.48 | 9.48 | 19.19 | 20.98 | 20.38 | 18.58 | 38.67 | 21.43 | 20.79 | 18.74 | 26.39 | 15.25 | 12.61 | 17.08 | 18.23 | 7.08 | 9.31 |
| — | +60.8% | +28.0% | -6.8% | -58.4% | -49.0% | -50.4% | -2.1% | -2.0% | -0.9% | +46.6% | +40.5% | +64.9% | +9.8% | +44.8% | +115.3% | +35.4% | +311.7% | +72.6% | -35.8% | -41.2% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.4% | 81.2% | 81.4% | 84.9% | 86.1% | 85.6% | 84.7% | 85.1% | 86.8% | 86.5% | 86.2% | 81.7% | 83.9% | 83.9% | 82.4% | 85.2% | 86.0% | 87.0% | 83.8% | 78.7% | 84.8% |
| — | -5.1% | -3.8% | -0.2% | -0.8% | -1.0% | -1.8% | +4.2% | +3.5% | +3.0% | +4.6% | -4.1% | -2.5% | -3.5% | -1.7% | +8.3% | +1.5% | +2.2% | -1.5% | -5.1% | -0.8% | |
| Operating Margin | 24.9% | 30.1% | 17.8% | 22.7% | 27.4% | 29.4% | 19.5% | 26.1% | 31.7% | 30.2% | 23.9% | 30.6% | 36.0% | 32.2% | 31.7% | 38.5% | 41.7% | 45.7% | 43.4% | 53.3% | 53.5% |
| — | +2.6% | -8.7% | -13.3% | -13.7% | -2.6% | -18.2% | -14.6% | -12.0% | -6.3% | -24.7% | -20.6% | -13.6% | -29.6% | -26.9% | -27.7% | -22.1% | -29.8% | -1.4% | +10.7% | +16.5% | |
| Net Margin | 31.4% | 30.2% | 20.2% | 21.7% | 38.9% | 37.9% | 26.7% | 24.2% | 36.0% | 40.4% | 23.0% | 33.8% | 30.0% | 30.7% | 25.9% | 35.1% | 44.8% | 29.8% | 32.8% | 45.0% | 47.3% |
| — | -20.2% | -24.5% | -10.2% | +7.9% | -6.2% | +16.3% | -28.3% | +20.2% | +31.7% | -11.2% | -3.7% | -33.1% | +2.8% | -21.2% | -22.1% | -5.2% | -50.5% | -25.6% | -5.1% | +28.8% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 14.9% | 8.3% | 2.3% | 2.7% | 4.8% | 4.7% | 2.8% | 3.1% | 4.7% | 5.2% | 2.7% | 4.6% | 4.1% | 4.1% | 3.5% | 5.4% | 6.2% | 4.2% | 5.0% | 12.4% | 10.1% |
| — | +75.9% | -15.7% | -13.2% | +2.9% | -9.6% | +1.0% | -31.4% | +13.1% | +27.3% | -23.1% | -16.0% | -34.0% | -2.9% | -29.6% | -56.1% | -38.0% | -81.6% | -48.1% | +13.9% | +14.8% | |
| ROA | 11.5% | 6.3% | 1.8% | 2.1% | 3.7% | 3.7% | 2.1% | 2.4% | 3.6% | 4.1% | 2.1% | 3.6% | 3.2% | 3.2% | 2.8% | 4.2% | 4.8% | 3.2% | 3.8% | 9.1% | 7.2% |
| — | +72.8% | -16.8% | -14.3% | +2.2% | -9.6% | +0.3% | -31.3% | +13.7% | +27.5% | -22.4% | -15.5% | -33.1% | +0.2% | -26.6% | -53.6% | -33.7% | -79.8% | -41.1% | +31.3% | +31.0% | |
| ROIC | 8.9% | 6.2% | 1.6% | 2.1% | 2.5% | 2.7% | 1.5% | 2.5% | 3.0% | 2.9% | 2.1% | 3.1% | 3.6% | 3.2% | 3.4% | 4.6% | 4.5% | 5.0% | 5.1% | 11.3% | 8.6% |
| — | +129.3% | +2.6% | -14.6% | -16.9% | -5.1% | -28.7% | -18.7% | -17.1% | -11.7% | -37.1% | -33.3% | -19.9% | -35.1% | -33.8% | -59.2% | -47.4% | -71.2% | -24.4% | +46.7% | +11.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.06 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.11 | 0.12 | 0.13 | 0.13 | 0.14 | 0.14 | 0.16 |
| — | -30.7% | -6.4% | -6.0% | -5.2% | -5.7% | -8.1% | -11.5% | -15.0% | -14.8% | -12.9% | -12.7% | -13.9% | -13.8% | -15.2% | -17.1% | -19.4% | -26.8% | -39.8% | -41.2% | -41.2% | |
| Debt / EBITDA | 0.66 | 0.00 | 3.53 | 2.64 | 2.33 | 2.23 | 3.76 | 2.42 | 2.08 | 2.27 | 3.12 | 2.32 | 2.05 | 2.41 | 2.45 | 1.91 | 2.05 | 1.96 | 1.98 | 0.99 | 1.41 |
| — | -100.0% | -6.2% | +9.0% | +11.9% | -1.9% | +20.5% | +4.3% | +1.2% | -5.9% | +27.4% | +21.7% | +0.0% | +23.4% | +23.5% | +91.9% | +46.0% | +147.8% | -13.2% | -54.7% | -42.0% | |
| Current Ratio | 4.13 | 3.34 | 3.57 | 4.13 | 4.06 | 4.60 | 4.93 | 4.73 | 5.28 | 5.44 | 5.27 | 5.69 | 5.18 | 5.45 | 5.45 | 5.06 | 5.36 | 5.12 | 4.76 | 3.56 | 3.71 |
| — | -27.5% | -27.6% | -12.8% | -23.1% | -15.5% | -6.5% | -16.9% | +2.0% | -0.2% | -3.4% | +12.5% | -3.4% | +6.5% | +14.7% | +41.9% | +44.5% | +43.2% | +52.2% | -1.7% | -4.7% | |
| Quick Ratio | 3.39 | 2.78 | 2.96 | 3.39 | 3.33 | 3.72 | 4.03 | 3.95 | 4.46 | 4.62 | 4.51 | 4.94 | 4.47 | 4.64 | 4.67 | 4.29 | 4.52 | 4.39 | 4.09 | 3.07 | 3.16 |
| — | -25.4% | -26.6% | -14.1% | -25.3% | -19.4% | -10.6% | -20.0% | -0.2% | -0.5% | -3.4% | +15.0% | -1.2% | +5.8% | +14.1% | +39.9% | +43.3% | +44.2% | +67.0% | +5.2% | +1.1% | |
| Interest Coverage | 120.42 | 99.30 | 65.43 | 86.55 | 92.36 | 422.86 | 105.02 | 92.25 | 109.19 | 111.01 | 44.52 | 63.71 | 63.40 | 58.30 | 48.67 | 77.13 | 99.68 | 74.53 | 79.02 | 178.55 | 128.93 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying REGN stock.
Regeneron Pharmaceuticals, Inc.'s current P/E is 17.7x. The average P/E over the last 4 quarters is 19.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Regeneron Pharmaceuticals, Inc.'s current operating margin is 24.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Regeneron Pharmaceuticals, Inc.'s business trajectory between earnings reports.